Sonoma Pharmaceuticals, Inc.

SNOA Healthcare Drug Manufacturers Specialty & Generic

Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.

1.13 0.02 −1.74%
Market cap
$5.5M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−18.52
Beneish M
−1.69
Dividend safety
n/a
Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24 Mar '25 Mar '26
Piotroski F-Score
5 3 4 2 3 2 5 4 5 3
P/E ratio
3.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
2.36 1.02 0.40 0.40 0.80 0.84 0.25 0.11 0.19 0.18
Altman Z-Score
(3.62) (9.65) (15.73) (16.19) (14.63) (12.75) (15.47) (17.82) (19.15) (18.52)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(11.17) (23.10) (36.60) (38.60) (36.06) (29.40) (34.87) (40.45) (44.32) (44.40)
P/Operating CF
(11.25) (5.57) (2.79) (2.02) (10.05) (7.63) (1.36) 8.98 (28.61) (6.91)
Beneish M-Score
2.72 (2.99) (1.67) (1.88) (2.98) (2.70) (1.93) (3.22) (4.09) (1.69)
P/B ratio
1.42 1.11 0.73 1.29 2.77 1.22 0.42 0.22 0.62 1.16
Price to Tangible BV
1.42 1.11 0.73 1.29 2.77 1.22 0.42 0.22 0.62 1.16
EV/Sales
1.03 0.44 0.23 0.27 0.67 0.35 0.00 (0.11) (0.18) 0.07
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.31 0.72 0.00
EV/Operating CF
(1.62) (0.59) (0.37) (1.04) (3.71) (1.03) 0.01 0.59 29.08 (0.33)
EV/FCF
(1.54) (0.58) (0.36) (1.00) (3.52) (1.00) 0.01 0.59 15.23 (0.31)
Quick Ratio
5.95 3.56 2.00 1.62 1.72 1.68 1.72 1.62 1.86 1.02
Current Ratio
6.89 4.98 3.48 2.60 3.18 2.82 3.71 3.37 3.09 2.50
Net Debt/EBITDA
1.35 0.71 0.31 0.42 0.72 1.16 0.76 0.62 1.50 1.03
Debt/Assets
1.32% 2.11% 2.31% 4.92% 12.72% 4.29% 2.66% 2.19% 0.00% 0.00%
Debt/Equity
0.02 0.03 0.03 0.13 0.36 0.09 0.05 0.05 0.00 0.00
Asset Turnover
0.65 0.75 1.13 1.24 1.26 0.75 0.76 0.82 1.01 1.41
Operating CF/Net income
(0.88) 0.87 0.99 1.39 0.86 0.84 1.19 0.50 0.03 1.24
Capex/Depreciation
(1.59) (0.38) (0.22) (0.66) (0.79) (0.74) (2.15) (0.01) (0.58) (1.38)
Interest Coverage
(4,324.67) (354.72) (341.15) (461.87) (215.56) — (285.62) — — —
ROE
58.75% (77.96%) (91.40%) (41.06%) (71.90%) (72.35%) (61.78%) (68.51%) (65.55%) (84.60%)
ROA
47.24% (64.16%) (70.11%) (22.81%) (26.74%) (30.07%) (29.37%) (31.22%) (24.32%) (22.96%)
ROIC
(188.31%) (156.51%) (98.63%) (174.36%) (70.70%) (174.46%) (62.25%) (88.18%) 0.00% (220.99%)
Return on Tangible Assets
45.03% (101.41%) (122.49%) (41.77%) (42.63%) (46.53%) (48.74%) (52.59%) (39.39%) (41.90%)
Average Days of Receivables
59.99 33.68 66.98 80.89 54.98 69.57 70.73 83.06 57.02 47.23
Research and Development Expense of Revenue
12.29% 9.45% 8.00% 7.47% 2.98% 0.99% 1.56% 14.69% 12.70% 11.63%
Selling, General and Administrative Expense of Revenue
133.07% 119.61% 98.15% 79.06% 50.74% 77.25% 66.61% 59.48% 51.52% 38.94%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
17.49% 15.01% 8.62% 4.68% 1.99% 3.03% 5.04% 4.05% 1.57% 1.31%
Graham Net Nets
0.61 0.73 1.12 0.46 0.23 0.59 1.67 2.89 1.24 0.34
Graham Number
2,850.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
30.69% (84.23%) (165.47%) (45.65%) (19.92%) (45.39%) (158.16%) (486.67%) (141.55%) (88.73%)
Free Cash Flow Yield
(28.23%) (74.43%) (154.46%) (66.24%) (23.98%) (41.20%) (193.05%) (175.82%) (6.18%) (115.00%)
Revenue per Share
545.74 661.03 410.61 242.60 186.66 95.16 78.21 27.99 11.51 11.60
Operating CF per Share
(347.53) (493.61) (253.61) (62.12) (33.85) (32.01) (36.25) (5.27) (0.07) (2.34)
Capex per Share
(16.77) (7.42) (2.16) (2.79) (1.79) (1.03) (1.59) 0.00 (0.06) (0.11)
Free Cash Flow per Share
(364.30) (501.03) (255.78) (64.91) (35.64) (33.04) (37.84) (5.27) (0.14) (2.45)
Cash per Share
743.02 399.44 79.85 49.95 42.28 55.73 22.51 6.87 4.33 1.42
Shareholders Equity per Share
911.96 608.17 227.03 76.10 53.74 65.54 47.01 13.49 3.55 1.84
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
911.96 608.17 227.03 76.10 53.74 65.54 47.01 13.49 3.55 1.84
Free Cash Flow
(8.56) (12.63) (11.82) (4.80) (3.56) (4.38) (6.42) (2.40) (0.17) (4.12)
Working Capital
19.36 12.99 8.91 7.55 8.91 10.61 10.08 8.83 8.55 7.27
Capital Expenditures
(0.39) (0.19) (0.10) (0.21) (0.18) (0.14) (0.27) 0.00 (0.08) (0.19)
Net Current Asset Value
18.62 12.37 8.54 3.35 3.36 6.28 5.54 3.95 3.37 1.24
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.30 0.69 0.00
Capex to Sales
0.03 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.20 0.43 0.62 0.85 0.63 0.58 0.26 0.48 0.61 0.45
Cash ROIC
(21.82%) (48.94%) (81.43%) (47.82%) (30.96%) (25.95%) (52.51%) (25.03%) (1.72%) (75.08%)
Accounts Receivable Turnover
7.09 9.14 7.56 4.81 5.50 4.84 5.33 4.66 5.57 8.21
Accounts Payable Turnover
5.52 7.40 7.99 5.90 6.29 5.06 7.09 11.04 11.31 8.42
Inventory Turnover
3.75 3.68 3.22 3.51 5.12 3.33 3.19 2.87 3.13 3.69
Average Days of Payables
64.00 49.67 45.40 76.94 53.50 69.36 34.90 27.73 39.42 57.94
Days of Inventory on Hand
113.27 111.87 123.32 81.18 76.51 112.56 118.61 124.21 120.59 110.01
Average Receivables
1.81 1.82 2.51 3.73 3.39 2.61 2.49 2.74 2.57 2.38
Average Payables
1.30 1.26 1.26 1.66 1.92 1.71 1.24 0.72 0.78 1.44
Average Inventory
1.91 2.54 3.14 2.80 2.36 2.60 2.76 2.79 2.82 3.28
Average Assets
19.63 22.33 16.83 14.50 14.77 16.92 17.54 15.49 14.22 13.83
Average Common Equity
15.79 18.38 12.91 8.06 5.49 7.03 8.34 7.06 5.27 3.75

Fold the line items

Columns are period end dates